搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Targeted Oncology
1 天
CRT Adds No RFS Benefit Over Chemotherapy in Resected Gallbladder Cancer
Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.
Targeted Oncology
1 天
ASCEND Trial of Certepetide Plus Chemo Fails to Improve PFS in Metastatic PDAC
Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...
Targeted Oncology
2 天
Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion
The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...
Targeted Oncology
2 天
Patient Case 2: A 65-Year-Old Patient With Standard-Risk, Transplant-Eligible NDMM
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...
Targeted Oncology
2 天
Surufatinib Plus TAS-102 Improves Survival in Refractory Metastatic PDAC
Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...
Targeted Oncology
4 天
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
Targeted Oncology
2 天
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
Targeted Oncology
5 天
What to Watch Out for at ASCO GI 2025: Key Abstracts for Community Oncologists
Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.
Targeted Oncology
5 天
Long-Term Follow-Up of Ibrutinib/Venetoclax Provides Durable Survival in CLL/SLL
In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...
Targeted Oncology
6 天
OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...
Targeted Oncology
6 天
Kim Evaluates New Regimens for EGFR+ Lung Cancer
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
Targeted Oncology
6 天
Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈